Glucocorticoids Disrupt Skeletal Angiogenesis Through Transrepression of NF-κB-Mediated Preosteoclast Pdgfb Transcription in Young Mice
Related Experiment Video
Updated: Dec 28, 2025

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
Published on: September 27, 2024
Yi Peng1,2, Shan Lv2,3, Yusheng Li4
1Department of Orthopedic Surgery, The Third Xiangya Hospital, Central South University, Changsha, China.
Abstract:
In the growing skeleton, angiogenesis is intimately coupled with osteogenesis. Chronic, high doses of glucocorticoids (GCs) are associated with decreased bone vasculature and induce osteoporosis and growth failure. The mechanism of GC-suppression of angiogenesis and relationship to osteoporosis and growth retardation remains largely unknown. Type H vessels, which are regulated by preosteoclast (POC) platelet-derived growth factor-BB (PDGF-BB), are specifically coupled with bone formation and development. We determined the effect of GCs on POC synthesis of PDGF-BB in relation to type H vessel formation, bone mass, and bone growth in the distal femur of 2-week-old young mice receiving prednisolone or vehicle for 2, 4, or 6 weeks. After 2 weeks of prednisolone, the number of POCs were unchanged while POC synthesis of PDGF-BB was reduced. Longer treatment with prednisolone reduced POCs numbers and PDGF-BB. These changes were associated with a reduction in type H vessels, bone formation rate, bone mass, and bone length at each time point. In vitro, excessive concentrations of prednisolone (10-6 M) resulted in decreased PDGF-BB concentration and POC numbers. Conditioned medium from POC cultures treated with control concentration of prednisolone (10-7 M) or recombinant PDGF-BB stimulated endothelial tube formation, whereas conditioned medium from control concentration of prednisolone-treated POC cultures neutralized by PDGF-BB antibody or excessive prednisolone inhibited endothelial tube formation. Administration of excessive prednisolone attenuated the P65 subunit of nuclear factor kappa B (NF-κB) binding to the Pdgfb promoter, resulting in lower Pdgfb transcription. Co-treatment with excessive prednisolone and the glucocorticoid receptor (GR) antagonist (RU486), GR siRNA, or TNFα rescued NF-κB binding to the Pdgfb promoter and endothelial tube formation. These results indicate that PDGF-BB synthesis in POCs is suppressed by GCs through transrepression of GR/NF-κB, thus inhibiting type H vessel formation and associated osteoporosis and growth failure. © 2020 American Society for Bone and Mineral Research.
Insights
Glucocorticoids suppress platelet-derived growth factor-BB (PDGF-BB) in preosteoclasts, inhibiting blood vessel formation and causing bone loss and growth failure in young mice.
Area of Science:
- Skeletal biology
- Endocrinology
- Vascular biology
Background:
- Angiogenesis is crucial for skeletal development, closely linked with osteogenesis.
- Glucocorticoids (GCs) impair bone vasculature, leading to osteoporosis and growth retardation.
- The precise mechanisms of GC-induced angiogenesis suppression remain unclear.
Purpose of the Study:
- To investigate how GCs affect platelet-derived growth factor-BB (PDGF-BB) synthesis in preosteoclasts (POCs).
- To determine the relationship between GC-induced changes in PDGF-BB and type H vessel formation, bone mass, and growth.
- To elucidate the molecular pathways involved in GC-mediated suppression of PDGF-BB and angiogenesis.
Main Methods:
- Prednisolone treatment in young mice for varying durations.
- Analysis of POC numbers, PDGF-BB levels, type H vessels, bone mass, and growth.
- In vitro studies using POC cultures and endothelial cells, investigating the role of NF-κB and GR signaling.
Main Results:
- Prednisolone reduced POC synthesis of PDGF-BB, decreased type H vessels, bone formation, bone mass, and bone length.
- Excessive prednisolone inhibited PDGF-BB production and POC numbers in vitro.
- GCs suppressed PDGF-BB transcription via transrepression of NF-κB binding to the Pdgfb promoter, mediated by the glucocorticoid receptor (GR).
Conclusions:
- Glucocorticoids suppress PDGF-BB synthesis in preosteoclasts through GR/NF-κB transrepression.
- This suppression inhibits type H vessel formation, leading to osteoporosis and growth failure.
- Targeting this pathway may offer therapeutic strategies for GC-induced bone diseases.
More Related Videos
07:38Adult Zebrafish Injury Models to Study the Effects of Prednisolone in Regenerating Bone Tissue
Published on: October 18, 2018
09:34Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair
Published on: September 7, 2017
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
TGF - β Signaling Pathway